Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Advances in DNA repair in cancer therapy / / Lawrence Panasci, Raquel Aloyz, Moulay Alaoui-Jamali, editors
| Advances in DNA repair in cancer therapy / / Lawrence Panasci, Raquel Aloyz, Moulay Alaoui-Jamali, editors |
| Edizione | [1st ed. 2013.] |
| Pubbl/distr/stampa | New York, : Springer, 2013 |
| Descrizione fisica | 1 online resource (316 p.) |
| Disciplina |
616.99
616.99/4061 616.99406 |
| Altri autori (Persone) |
PanasciLawrence
AloyzRaquel Alaoui-JamaliMoulay |
| Collana | Cancer drug discovery and development |
| Soggetto topico |
Cancer - Treatment - Genetic aspects
DNA repair |
| ISBN |
1-283-93366-7
1-4614-4741-0 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Preface -- Repair of DNA Interstrand Cross-links Produced by Cancer Chemotherapeutic Drugs -- DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy? -- Growth factor receptor signaling, DNA damage response, and cancer cell susceptibility to chemotherapy and relapses -- The relationship between DNA-repair genes, cellular radiosensitivity and the response of tumors and normal tissues to radiotherapy -- Important Roles of ERCC1 in DNA Repair and Targeted Therapy -- The role of BRCA1 and BRCA2 in anticancer drug therapy -- DNA-PK in CLL Chemotherapy -- Poly(ADP) ribose polymerase at the interface of DNA damage signalling and DNA repair -- Cellular protection against the antitumor drug bleomycin -- ATR as a Therapeutic Target -- Telomeres, Telomerase and DNA Damage Response in Cancer Therapy -- RAD51 is a key protein of DNA repair and homologous recombination in humans -- Index. |
| Record Nr. | UNINA-9910437992603321 |
| New York, : Springer, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances in Regional Cancer Therapy : : 3rd International Conference on Advances in Regional Cancer Therapy, Ulm, September 1987 / / editors, J. Kreidler, K.H. Link, K.R. Aigner
| Advances in Regional Cancer Therapy : : 3rd International Conference on Advances in Regional Cancer Therapy, Ulm, September 1987 / / editors, J. Kreidler, K.H. Link, K.R. Aigner |
| Autore | Kreidler J |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Basel : , : S. Karger, , 1988 |
| Descrizione fisica | 1 online resource (X + 226 pages) : : 52 figures, 65 tables |
| Disciplina | 616.99/4061 |
| Altri autori (Persone) |
KreidlerJoachim
LinkK. H (Karl Heinz) AignerK <1947-> (Karl) |
| Soggetto topico |
Oncology
Pharmaceutics Pharmacology Chemotherapy Gastroenterology Hepatology Neurology Otorhinolaryngology Radiology Surgery |
| ISBN |
9783318042788
3318042781 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910135640203321 |
Kreidler J
|
||
| Basel : , : S. Karger, , 1988 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Anticancer therapeutics / / edited by Sotiris Missailidis
| Anticancer therapeutics / / edited by Sotiris Missailidis |
| Pubbl/distr/stampa | Chichester ; ; Hoboken, NJ, : John Wiley & Sons, 2008 |
| Descrizione fisica | 1 online resource (426 p.) |
| Disciplina |
616.99/4061
616.994061 |
| Altri autori (Persone) | MissailidisSotiris |
| Soggetto topico |
Cancer - Chemotherapy
Antineoplastic agents |
| ISBN |
1-281-93942-0
9786611939427 0-470-69704-0 0-470-69703-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Anticancer Therapeutics; Contents; Forward; Acknowledgements; List of contributors; SECTION I: Development of Anticancer Therapeutics; 1 Exploring the Potential of Natural Products in Cancer Treatment; 1.1 Introduction; 1.2 Sources; 1.3 Different Approaches to the Search for Bioactive Natural Products; 1.4 Methodologies of Lead Compound or New Drug Identification; 1.5 Chemoprevention - A New Area for Natural Product Research; 1.6 Concluding Remarks; 2 Combinatorial Approaches to Anticancer Drug Design; 2.1 Introduction; 2.2 Combinatorial Approaches for Small Molecule Drug Design
2.3 Display Technologies2.4 Aptamer Selection; 2.5 Conclusions; 3 Rational Approaches to Anticancer Drug Design/in silico Drug Development; 3.1 Introduction; 3.2 Approaches to the Drug Discovery Process in Anticancer Research; 3.3 Ligand-based Examples; 3.4 Structure-based Examples; 3.5 Conclusions; SECTION II: Anticancer Therapeutics; 4 Introduction to Anticancer Therapeutics; 4.1 Problems in cancer; 4.2 Cancer treatments; 4.3 Classification of chemotherapy drugs; 5 Platinum Drugs; 5.1 Cisplatin; 5.2 Lipoplatin; 5.3 Carboplatin; 5.4 Oxaliplatin; 5.5 Lipoxal; 5.6 New Platinum Compounds 5.7 Cisplatin Resistance and Chemotherapy6 Antimicrotubule Agents; 6.1 Taxanes; 6.2 Vinca Alkaloids; 6.3 Mechanisms of Resistance to Antimicrotubule Agents; 7 Antimetabolites in Cancer Therapy; 7.1 Introduction; 7.2 Folate Antagonists; 7.3 Pyrimidine Antagonists; 7.4 Purine Antagonists; 7.5 Summary; 8 Antitumour Antibiotics; 8.1 Introduction; 8.2 Actinomycin; 8.3 Mitomycin C; 8.4 Bleomycin; 8.5 Anthracyclines; 8.6 Trabectedin (Ecteinascidin, ET-743); 8.7 Camptothecins; 8.8 Podophyllotoxins; 9 Alkylating Agents; 9.1 Introduction; 9.2 Nitrogen Mustards; 9.3 Methylmelamines and Ethylenimines 9.4 Methylhydrazine Derivatives9.5 Alkylsulfonates; 9.6 Nitrosoureas; 9.7 Triazenes; 10 Hormone Therapies; 10.1 Introduction; 10.2 Oestrogen Receptor Targeted Therapeutics; 10.3 Progesterone-Targeted Therapy; 10.4 Neuroendocrine Tumours; 11 Photodynamic Therapy of Cancer; 11.1 Introduction; 11.2 Photosensitizers; 11.3 Outlook; 11.4 Acknowledgement; 12 Target-directed Drug Discovery; 12.1 Introduction; 12.2 Tyrosine Kinases - Role and Significance in Cancer; 12.3 Targeted Therapy for the Treatment of Non-small Cell Lung Cancer (NSCLC) 12.4 Targeted Therapy for the Treatment of Chronic Myeloid Leukaemia12.5 Targeted Therapy for the Treatment of Breast Cancer; 12.6 Angiogenesis; 12.7 Targeting Cell Cycling; 12.8 Targeting Apoptosis; 12.9 Targeting mTOR; 12.10 The Future of Molecularly Targeted Therapy; 13 Tumour Hypoxia: Malignant Mediator; 13.1 Introduction; 13.2 Hypoxia Inducible Factor-1 and Hypoxia; 13.3 HIF-1α Post-translational Changes; 13.4 How Genetics Can Modify HIF; 13.5 How Tumours Overcome Hypoxia with HIF-1; 13.6 HIF-1 Therapeutics; 13.7 Conclusion; 14 Resistance to Chemotherapy Drugs; 14.1 Introduction 14.2 What are the Factors Limiting the Efficacy of Cancer Chemotherapy Treatment? |
| Record Nr. | UNINA-9910144091303321 |
| Chichester ; ; Hoboken, NJ, : John Wiley & Sons, 2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer chemotherapy [[electronic resource] /] / Rachel Airley
| Cancer chemotherapy [[electronic resource] /] / Rachel Airley |
| Autore | Airley Rachel |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009 |
| Descrizione fisica | 1 online resource (362 p.) |
| Disciplina |
616.99/4061
616.994061 |
| Soggetto topico |
Cancer - Chemotherapy
Chemotherapy |
| ISBN |
1-282-11217-1
9786612112171 0-470-09254-8 0-470-09256-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cancer Chemotherapy; Contents; Preface; 1 Cancer epidemiology; 1.1 Cancer incidence, prevalence and mortality; 1.2 Childhood cancers; 1.3 Global epidemiology; 2 Histopathology of cancer; 2.1 Introduction; 2.2 Malignant, benign and normal (non-malignant) tissue; 2.3 Cell death; 3 Carcinogenesis, malignant transformation and progression; 3.1 Introduction; 3.2 Chemical carcinogenesis; 4 Molecular biology of cancer: oncogenes and tumour suppressor genes; 4.1 Introduction; 4.2 Oncogenesis; 4.3 Tumour suppressor genes; 5 Tumour metastasis: a convergence of many theories; 5.1 Introduction
5.2 Detachment and migration from the primary tumour5.3 Intravasation; 5.4 Transport; 5.5 Extravasation; 5.6 Growth of the metastatic tumour mass; 6 Health professionals in the treatment of cancer; 6.1 Introduction; 6.2 Pathology; 6.3 Radiology; 6.4 Role of the surgical oncologist; 6.5 Oncology pharmacy; 6.6 Oncology nursing; 6.7 The NHS Cancer Plan; 7 Principles of cancer chemotherapy; 7.1 Introduction; 7.2 Timing of chemotherapy; 7.3 Biomarkers and their uses; 7.4 Clinical assessment of biomarkers; 7.5 Pharmacogenetics and pharmacogenomics of cancer chemotherapy 8 Classical anticancer agents8.1 Introduction; 8.2 Alkylating agents; 8.3 Antimetabolites; 8.4 Agents derived from natural or semisynthetic products; 8.5 Hormonal anticancer agents; 8.6 Clinically used chemotherapy regimens; 9 The philosophy of cancer research; 9.1 Introduction; 9.2 Structure of cancer research organizations in the United Kingdom; 9.3 Cancer research in the United States; 10 Novel anticancer agents; 10.1 Introduction; 10.2 Target validation; 10.3 Identification and optimization of lead drugs; 10.4 Preclinical pharmacology; 11 Clinical trials; 11.1 Introduction 11.2 Evaluation of treatment response11.3 Assessment of vascularity and angiogenesis by nuclear medicine technology; 12 Tumour hypoxia; 12.1 Introduction; 12.2 Bioreductive drugs; 12.3 Inhibitors of HIF-1 and HIF-1-regulated genes; 13 Antiangiogenic and antivascular agents; 13.1 History of angiogenesis as a therapeutic target; 13.2 Anti-angiogenic drug targets; 13.3 The return of thalidomide; 13.4 Monoclonal antibodies as anti-angiogenic agents; 13.5 The hollow fibre assay as a drug screen for anti-angiogenic drugs; 13.6 Vascular disrupting agents; 14 Tyrosine kinase inhibitors 14.1 Introduction14.2 Tyrosine kinase inhibitors targeting angiogenesis; 14.3 Non-receptor tyrosine kinase inhibitors; 15 Ras inhibitors; 16 Inhibitors of the Akt/PKB pathway; 17 Targeting stress proteins: HSP90 inhibitors; 18 The proteasome; 18.1 Introduction; 18.2 The proteasome as a target for novel drug strategies; 18.3 Ubiquitylation as a target; 19 Checkpoint protein kinases as novel targets - mammalian target of rapamycin (mTOR); 19.1 Mammalian target of rapamycin; 19.2 Structure and activation of mTOR; 19.3 Novel anticancer agents targeting mTOR; 20 Telomerase 21 Histone deacetylase: an epigenetic drug target |
| Record Nr. | UNINA-9910782612503321 |
|
Airley Rachel
|
||
| Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer chemotherapy and biotherapy : principles and practice / / Bruce A. Chabner, Dan L. Longo
| Cancer chemotherapy and biotherapy : principles and practice / / Bruce A. Chabner, Dan L. Longo |
| Edizione | [Fifth edition.] |
| Pubbl/distr/stampa | Philadelphia : , : Wolters Kluwer Health/Lippincott Williams & Wilkins, , [2011] |
| Descrizione fisica | 1 online resource (836 p.) |
| Disciplina | 616.99/4061 |
| Altri autori (Persone) |
ChabnerBruce
LongoDan L <1949-> (Dan Louis) |
| Soggetto topico |
Cancer - Chemotherapy
Cancer - Immunotherapy Antineoplastic agents Biological response modifiers |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-4511-2453-8
1-4698-7482-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | section I. Basic principles of cancer treatment -- section II. Cytotoxic agents -- section III. Molecularly targeted therapies -- section IV. Immunologic agents -- section V. Hormonal therapy -- section VI. Supportive care -- section VII. Survivorship. |
| Record Nr. | UNINA-9910463686403321 |
| Philadelphia : , : Wolters Kluwer Health/Lippincott Williams & Wilkins, , [2011] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer chemotherapy and biotherapy [[electronic resource] ] : principles and practice / / [edited by] Bruce A. Chabner, Dan L. Longo
| Cancer chemotherapy and biotherapy [[electronic resource] ] : principles and practice / / [edited by] Bruce A. Chabner, Dan L. Longo |
| Edizione | [5th ed.] |
| Pubbl/distr/stampa | Philadelphia, : Wolters Kluwer Health/Lippincott Williams & Wilkins, c2011 |
| Descrizione fisica | 1 online resource (836 p.) |
| Disciplina | 616.99/4061 |
| Altri autori (Persone) |
ChabnerBruce
LongoDan L <1949-> (Dan Louis) |
| Soggetto topico |
Cancer - Chemotherapy
Cancer - Immunotherapy Antineoplastic agents Biological response modifiers Neoplasms - drug therapy Antineoplastic Agents - therapeutic use Biological Products - therapeutic use |
| ISBN |
1-4511-2453-8
1-4698-7482-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | section I. Basic principles of cancer treatment -- section II. Cytotoxic agents -- section III. Molecularly targeted therapies -- section IV. Immunologic agents -- section V. Hormonal therapy -- section VI. Supportive care -- section VII. Survivorship. |
| Record Nr. | UNINA-9910788958503321 |
| Philadelphia, : Wolters Kluwer Health/Lippincott Williams & Wilkins, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer immunotherapy : immune suppression and tumor growth / / [edited by] George Prendergast, Elizabeth M. Jaffee
| Cancer immunotherapy : immune suppression and tumor growth / / [edited by] George Prendergast, Elizabeth M. Jaffee |
| Pubbl/distr/stampa | Amsterdam ; ; Boston, : Academic Press, c2007 |
| Descrizione fisica | 1 online resource (429 p.) |
| Disciplina | 616.99/4061 |
| Altri autori (Persone) |
PrendergastGeorge C
JaffeeElizabeth M |
| Soggetto topico |
Cancer - Immunotherapy
Antineoplastic agents - Therapeutic use Tumors - Immunological aspects |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1281020451
9786611020453 0080521851 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front cover; Cancer Immunotherapy: Immune Suppression and Tumor Growth; Copyright page; Table of contents; Contributors; PART I: PRINCIPLES OF CANCER IMMUNOBIOLOGY; CHAPTER 1: Introduction; I. OVERVIEW; II. HISTORICAL BACKGROUND; III. LOOKING AHEAD: MARRYING CHEMOTHERAPY AND IMMUNOTHERAPY; IV. PARTS OF THE BOOK; References; Further Reading; CHAPTER 2: Cancer Immunoediting: From Immune Surveillance to Immune Escape; I. INTRODUCTION; II. CANCER IMMUNE SURVEILLANCE; III. CANCER IMMUNOEDITING; IV. CONCLUDING REMARKS; References
CHAPTER 3: Immunosurveillance: Innate and Adaptive Antitumor ImmunityI. INTRODUCTION; II. INNATE ANTITUMOR RESPONSES; III. INNATE IMMUNE CELLS; IV. ADAPTIVE ANTITUMOR RESPONSES; V. THE INTERPLAY OF INNATE AND ADAPTIVE ANTITUMOR IMMUNITY; VI. CONCLUSION; References; CHAPTER 4: Cytokine Regulation of Immune Tolerance to Tumors; I. INTRODUCTION; II. CYTOKINE REGULATION OF IMMUNE TOLERANCE TO TUMORS; III. SUMMARY AND FUTURE PERSPECTIVES; References; CHAPTER 5: Immunological Sculpting:Natural Killer Cell Receptorsand Ligands; I. INTRODUCTION; II. ACTIVATING HUMAN NK RECEPTORS III. INHIBITORY NK RECEPTORSIV. THE LY49 RECEPTOR FAMILY; V. IMMUNOTHERAPY APPROACHES; VI. CONCLUSION; References; Further Reading; CHAPTER 6: Immune Escape:Immunosuppressive Networks; I. INTRODUCTION; II. IMBALANCE BETWEEN MATURE DCs AND IMMATURE DCs; III. IMBALANCE BETWEEN STIMULATORY AND INHIBITORY B7 FAMILY MOLECULES; IV. IMBALANCE BETWEEN REGULATORY T CELLS AND CONVENTIONAL T CELLS; V. CONCLUDING REMARKS; References; PART II: CANCER THERAPEUTICS; CHAPTER 7: Cytotoxic Chemotherapy inClinical Treatment of Cancer; I. INTRODUCTION; II. DNA-DAMAGING AGENTS; III. ANTIMETABOLITES IV. ANTIMITOTICS V. CHEMOTHERAPY REGIMENS; References; Useful Web Sites; CHAPTER 8: Targeted Therapeutics in Cancer Treatment; I. INTRODUCTION; II. CELL CYCLE; III. THE MAPK FAMILY; IV. CHALLENGES IN THE CLINICAL DEVELOPMENT OF SIGNAL TRANSDUCTION INHIBITORS; References; CHAPTER 9: Concepts in Pharmacology and Toxicology; I. INTRODUCTION; II. CONCEPTS IN PHARMACOKINETICS; III. CONCEPTS IN TOXICOLOGY; IV. CLINICAL CONCERNS FOR PHARMACOLOGY AND SAFETY; V. CONCLUSION; References; Further Reading; CHAPTER 10: Cancer Immunotherapy:Challenges and Opportunities; I. INTRODUCTION II. PREREQUISITES FOR EFFECTIVE CANCER IMMUNOTHERAPY: IDENTIFYING TUMOR ANTIGENS III. ADOPTIVE ("PASSIVE") IMMUNOTHERAPY; IV. ACTIVE-SPECIFIC IMMUNOTHERAPY: VACCINES; V. CANCER-INDUCED IMMUNOSUPPRESSION IMPINGES ON IMMUNOTHERAPY; VI. CANCER IMMUNOTHERAPY IN MICE VERSUS HUMANS; VII. IMMUNOTHERAPY AND CANCER STEM CELLS; VIII. AUTOIMMUNITY RESULTING FROM CANCER IMMUNOTHERAPY; IX. CONCLUSION AND FUTURE CONSIDERATIONS; References; CHAPTER 11: Cancer Vaccines; I. INTRODUCTION; II. TUMOR ANTIGENS; III. SPONTANEOUS IMMUNITY TO CANCER; IV. TOLERAGENIC PRESSURE ON IMMUNITY TO CANCER V. IMMUNE RESPONSES TO CONVENTIONAL VACCINES |
| Record Nr. | UNINA-9910458644103321 |
| Amsterdam ; ; Boston, : Academic Press, c2007 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer immunotherapy : immune suppression and tumor growth / / [edited by] George Prendergast, Elizabeth M. Jaffee
| Cancer immunotherapy : immune suppression and tumor growth / / [edited by] George Prendergast, Elizabeth M. Jaffee |
| Pubbl/distr/stampa | Amsterdam ; ; Boston, : Academic Press, c2007 |
| Descrizione fisica | 1 online resource (429 p.) |
| Disciplina | 616.99/4061 |
| Altri autori (Persone) |
PrendergastGeorge C
JaffeeElizabeth M |
| Soggetto topico |
Cancer - Immunotherapy
Antineoplastic agents - Therapeutic use Tumors - Immunological aspects |
| ISBN |
1281020451
9786611020453 0080521851 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front cover; Cancer Immunotherapy: Immune Suppression and Tumor Growth; Copyright page; Table of contents; Contributors; PART I: PRINCIPLES OF CANCER IMMUNOBIOLOGY; CHAPTER 1: Introduction; I. OVERVIEW; II. HISTORICAL BACKGROUND; III. LOOKING AHEAD: MARRYING CHEMOTHERAPY AND IMMUNOTHERAPY; IV. PARTS OF THE BOOK; References; Further Reading; CHAPTER 2: Cancer Immunoediting: From Immune Surveillance to Immune Escape; I. INTRODUCTION; II. CANCER IMMUNE SURVEILLANCE; III. CANCER IMMUNOEDITING; IV. CONCLUDING REMARKS; References
CHAPTER 3: Immunosurveillance: Innate and Adaptive Antitumor ImmunityI. INTRODUCTION; II. INNATE ANTITUMOR RESPONSES; III. INNATE IMMUNE CELLS; IV. ADAPTIVE ANTITUMOR RESPONSES; V. THE INTERPLAY OF INNATE AND ADAPTIVE ANTITUMOR IMMUNITY; VI. CONCLUSION; References; CHAPTER 4: Cytokine Regulation of Immune Tolerance to Tumors; I. INTRODUCTION; II. CYTOKINE REGULATION OF IMMUNE TOLERANCE TO TUMORS; III. SUMMARY AND FUTURE PERSPECTIVES; References; CHAPTER 5: Immunological Sculpting:Natural Killer Cell Receptorsand Ligands; I. INTRODUCTION; II. ACTIVATING HUMAN NK RECEPTORS III. INHIBITORY NK RECEPTORSIV. THE LY49 RECEPTOR FAMILY; V. IMMUNOTHERAPY APPROACHES; VI. CONCLUSION; References; Further Reading; CHAPTER 6: Immune Escape:Immunosuppressive Networks; I. INTRODUCTION; II. IMBALANCE BETWEEN MATURE DCs AND IMMATURE DCs; III. IMBALANCE BETWEEN STIMULATORY AND INHIBITORY B7 FAMILY MOLECULES; IV. IMBALANCE BETWEEN REGULATORY T CELLS AND CONVENTIONAL T CELLS; V. CONCLUDING REMARKS; References; PART II: CANCER THERAPEUTICS; CHAPTER 7: Cytotoxic Chemotherapy inClinical Treatment of Cancer; I. INTRODUCTION; II. DNA-DAMAGING AGENTS; III. ANTIMETABOLITES IV. ANTIMITOTICS V. CHEMOTHERAPY REGIMENS; References; Useful Web Sites; CHAPTER 8: Targeted Therapeutics in Cancer Treatment; I. INTRODUCTION; II. CELL CYCLE; III. THE MAPK FAMILY; IV. CHALLENGES IN THE CLINICAL DEVELOPMENT OF SIGNAL TRANSDUCTION INHIBITORS; References; CHAPTER 9: Concepts in Pharmacology and Toxicology; I. INTRODUCTION; II. CONCEPTS IN PHARMACOKINETICS; III. CONCEPTS IN TOXICOLOGY; IV. CLINICAL CONCERNS FOR PHARMACOLOGY AND SAFETY; V. CONCLUSION; References; Further Reading; CHAPTER 10: Cancer Immunotherapy:Challenges and Opportunities; I. INTRODUCTION II. PREREQUISITES FOR EFFECTIVE CANCER IMMUNOTHERAPY: IDENTIFYING TUMOR ANTIGENS III. ADOPTIVE ("PASSIVE") IMMUNOTHERAPY; IV. ACTIVE-SPECIFIC IMMUNOTHERAPY: VACCINES; V. CANCER-INDUCED IMMUNOSUPPRESSION IMPINGES ON IMMUNOTHERAPY; VI. CANCER IMMUNOTHERAPY IN MICE VERSUS HUMANS; VII. IMMUNOTHERAPY AND CANCER STEM CELLS; VIII. AUTOIMMUNITY RESULTING FROM CANCER IMMUNOTHERAPY; IX. CONCLUSION AND FUTURE CONSIDERATIONS; References; CHAPTER 11: Cancer Vaccines; I. INTRODUCTION; II. TUMOR ANTIGENS; III. SPONTANEOUS IMMUNITY TO CANCER; IV. TOLERAGENIC PRESSURE ON IMMUNITY TO CANCER V. IMMUNE RESPONSES TO CONVENTIONAL VACCINES |
| Record Nr. | UNINA-9910784658103321 |
| Amsterdam ; ; Boston, : Academic Press, c2007 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The chemotherapy source book / / editor, Michael C. Perry ; associate editors, Donald C. Doll, Carl E. Freter
| The chemotherapy source book / / editor, Michael C. Perry ; associate editors, Donald C. Doll, Carl E. Freter |
| Edizione | [Fifth edition.] |
| Pubbl/distr/stampa | Philadelphia : , : Wolters Kluwer/Lippincott Williams & Wilkins, , [2012] |
| Descrizione fisica | 1 online resource (847 p.) |
| Disciplina | 616.99/4061 |
| Altri autori (Persone) |
PerryMichael C <1945-> (Michael Clinton)
DollDonald C FreterCarl E |
| Soggetto topico |
Cancer - Chemotherapy
Antineoplastic agents |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-4698-0343-7
1-4698-2777-8 1-4698-7468-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | section I. Scientific principles of chemotherapy -- section II. Routes of administration -- section III. Management of drug toxicity -- section IV. Drug administration -- section V. Current therapy of specific solid tumors -- section VI. Chemotherapy of hematologic malignancies -- section VII. Appendices. |
| Record Nr. | UNINA-9910464002603321 |
| Philadelphia : , : Wolters Kluwer/Lippincott Williams & Wilkins, , [2012] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The chemotherapy source book [[electronic resource] /] / editors, Michael C. Perry, associate editors, Donald C. Doll, Carl E. Freter
| The chemotherapy source book [[electronic resource] /] / editors, Michael C. Perry, associate editors, Donald C. Doll, Carl E. Freter |
| Edizione | [Fifth edition.] |
| Pubbl/distr/stampa | Philadelphia, : Wolters Kluwer/Lippincott Williams & Wilkins, c2012 |
| Descrizione fisica | 1 online resource (847 pages) |
| Disciplina | 616.99/4061 |
| Altri autori (Persone) |
PerryMichael C <1945-> (Michael Clinton)
DollDonald C FreterCarl E |
| Soggetto topico |
Cancer - Chemotheraphy
Antineoplastic agents Neoplasms - drug therapy Antineoplastic Agents - therapeutic use |
| ISBN |
1-4698-0343-7
1-4698-2777-8 1-4698-7468-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | section I. Scientific principles of chemotherapy -- section II. Routes of administration -- section III. Management of drug toxicity -- section IV. Drug administration -- section V. Current therapy of specific solid tumors -- section VI. Chemotherapy of hematologic malignancies -- section VII. Appendices. |
| Record Nr. | UNINA-9910788455203321 |
| Philadelphia, : Wolters Kluwer/Lippincott Williams & Wilkins, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
